Exlites Holdings International Inc is engaged in the consumer healthcare market and durable medical supply business... Show more
EXHI's Aroon Indicator triggered a bullish signal on July 24, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 99 similar instances where the Aroon Indicator showed a similar pattern. In of the 99 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
EXHI moved above its 50-day moving average on June 25, 2025 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for EXHI crossed bullishly above the 50-day moving average on June 27, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 20 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 18 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Moving Average Convergence Divergence Histogram (MACD) for EXHI turned negative on July 17, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 34 similar instances when the indicator turned negative. In of the 34 cases the stock turned lower in the days that followed. This puts the odds of success at .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EXHI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (7.892). EXHI has a moderately low P/E Ratio (0.000) as compared to the industry average of (29.460). EXHI's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (4.521). EXHI has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.032). P/S Ratio (0.000) is also within normal values, averaging (35.215).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EXHI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry MedicalDistributors